✦ LIBER ✦

Biomarker Profiles and Cytoplasmic Vacuolization as Predictors of Progression-Free Survival and Clinical Response to Neoadjuvant Chemotherapy in Patients with Epithelial Ovarian Cancer

✍ Scribed by A. Mahdavi; S. Chopra; M. Hunter; W. Brewster; I. Ramzy; K.S. Tewari

Book ID: 113961312
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 51 KB
Volume: 107
Category: Article
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2007.08.053

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Calpain-2 expression is associated with

Calpain-2 expression is associated with response to platinum based chemotherapy, progression-free and overall survival in ovarian cancer

✍ Sarah J. Storr; Sabreena Safuan; Caroline M. Woolston; Tarek Abdel-Fatah; Suha D 📂 Article 📅 2012 🏛 Carol Davila University of Medicine Bucharest, Rom 🌐 English ⚖ 335 KB

Survivin As a Predictive Biomarker of Co

Survivin As a Predictive Biomarker of Complete Pathologic Response to Neoadjuvant Chemotherapy in Patients With Stage II and Stage III Breast Cancer

✍ Cristiane Rios Petrarca; Andre T. Brunetto; Vinicius Duval; Adriana Brondani; Gi 📂 Article 📅 2011 🏛 CIG Media Group, LP. 🌐 English ⚖ 961 KB

CA125 level as a predictor of progressio

CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy

✍ Margrit M. Juretzka; Richard R. Barakat; Dennis S. Chi; Alexia Iasonos; Jakob Du 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 347 KB

Pharmacogenetic profiling of CD133 is as

Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy

✍ Pohl, A; El-Khoueiry, A; Yang, D; Zhang, W; Lurje, G; Ning, Y; Winder, T; Hu-Lie 📂 Article 📅 2012 🏛 Nature Publishing Group 🌐 English ⚖ 401 KB

A phase III randomized trial of BAY 12-9

A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: A National Cancer Institute of Canada Clinical Trials Group Study

✍ H. Hirte; I.B. Vergote; J.R. Jeffrey; R.N. Grimshaw; S. Coppieters; B. Schwartz; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 276 KB